ARTIFICIAL INTELLIGENCE
FOR EVERY STEP
OF PHARMACEUTICAL
RESEARCH AND DEVELOPMENT
FOR EVERY STEP
OF PHARMACEUTICAL
RESEARCH AND DEVELOPMENT
Integrated & Experimentally-Validated
Our mission is to accelerate drug discovery and drug development
We are a globally leading end-to-end generative AI-driven biotech company in terms of AIDD pipeline progress, with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary Pharma.AI platform across biology, chemistry and clinical development.
Our generative AI platform helps us to rapidly and efficiently advance our fully self-generated AIDD pipeline primarily composed of novel drug candidates.
Enabling multi-omics target discovery and deep biology analysis engine to considerably reduce required time
Find novel lead-like molecules through this automated, machine learning de-novo drug design and scalable engineering platform
Predict clinical trials success rate, recognize the weak points in trial design, while adopting the best practices in the industry
Discover and Prioritize
Generate
Design and predict
Novel Targets
Novel Molecules
Clinical Trials
INTRODUCING FULLY-INTEGRATED DRUG DISCOVERY SOFTWARE SUITE
Nobel Laureate Michael Levitt: How Early Protein Modeling Advanced to AI-Driven Drug Discovery with Insilico Medicine
Stanford professor Michael Levitt, PhD, a member of Insilico Medicine's Scientific Advisory Board, won the Nobel Prize in Chemistry in 2013 for his groundbreaking work in protein structure and protein folding using computer modeling.
In this lecture, Dr. Levitt describes how the work he began over 50 years ago has been vastly improved and expanded through the massive increase in computer speed and incredible advances in machine learning. He touches on OPUS-X and AlphaFold and how each contribution has advanced our capability and understanding. Now, says Dr. Levitt, Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline from A to Z. Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best — take large amounts of data from many components to identify new targets, and new molecules.
In this lecture, Dr. Levitt describes how the work he began over 50 years ago has been vastly improved and expanded through the massive increase in computer speed and incredible advances in machine learning. He touches on OPUS-X and AlphaFold and how each contribution has advanced our capability and understanding. Now, says Dr. Levitt, Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline from A to Z. Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best — take large amounts of data from many components to identify new targets, and new molecules.
“
Uncertainty is a good thing. By combining data with clever filtering we get certainty and options from uncertainty." Dr. Levitt sees massive possibilities ahead. "The protein-folding problem that was a very difficult problem for 50 years, and drug design, are all being dealt with in this global, all-encompassing way. And I am personally very, very optimistic."
NEWS
MEDIA COVERAGE
HONG KONG
Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong
NEW YORK
345 Park Avenue South,
2nd Floor Suite 006 New York,
NY 10010
2nd Floor Suite 006 New York,
NY 10010
MONTREAL
1250 René-Lévesque Ouest,
Suite 3710, Montréal, Québec,
Canada H3B 4W8
Suite 3710, Montréal, Québec,
Canada H3B 4W8
ABU DHABI
Level 6, Unit 08, Block A, IRENA HQ Building Masdar City, Abu Dhabi, United Arab Emirates